Morning Briefing
Summaries of health policy coverage from major news organizations
FDA OKs 4 More Flavored Nicotine Pouches
The Food and Drug Administration (FDA) on Tuesday granted marketing authorization to four new flavored nicotine pouches as part of the agency’s tobacco review pilot program launched last year. Four nicotine pouch products — Rich Berry 2 mg, Cappuccino 2 mg, Cappuccino 4 mg and Autumn Spice 2 mg — from Helix Innovations LLC received marketing authorization from the FDA. The authorizations are part of the agency’s pilot program launched in September 2025 meant to “streamline the review process for premarket tobacco product applications.” (Choi, 8/4)
It comes in flavors like "Cool Mint," "Smooth," and "Chill." It's on the Ferrari F1 race car. And it's addictive. A paperclip-sized pouch filled with bleach-white fibers and nicotine crystals placed between the lip and gum, leeches nicotine and other chemicals into the user's bloodstream — allowing anyone to use nicotine discreetly. (Kim, 8/5)
More pharma and tech updates —
Procter & Gamble Co. won the bidding war for supplement maker Thorne in a deal valued at $3.8 billion. L Catterton, which took the company private in 2023, said the all cash transaction is set to be completed in the fourth quarter of 2026, according to a statement Tuesday. (Brown, 8/4)
Aurora Therapeutics, a startup focused on building personalized gene-editing drugs, has scrapped its lead program and slashed staff, just seven months after it launched, STAT has learned. (Mast and DeAngelis, 8/4)
A peptide vaccine targeting KRAS mutations in pancreatic cancer showed preliminary evidence of activity in a small study of high-risk patients. The vaccine elicited KRAS-specific T-cell responses in 18 of 20 patients with mutations associated with pancreatic ductal adenocarcinoma (PDAC). (Bankhead, 8/4)
With more than 333,000 new cases every year, prostate cancer is the most frequently diagnosed cancer in the U.S., and by far the most common among men. It is also the least deadly: Only about 4% of prostate cancers end up being lethal, and the 5-year survival rate is about 99%. (Merelli, 8/5)
A meta-analysis of 11 studies concludes that self-testing for human papilloma virus (HPV) using urine or vaginal samples accurately detects pre-cancerous cells caused by HPV, also known as high-grade squamous intraepithelial lesions (HSIL+). This paper, published in the Journal of Obstetrics and Gynaecology Research, reinforces the precision of self-collection testing for HPV, which could increase access to screening. (Holohan, 8/4)
